As a part of its second financing round, Icon Genetics AG has secured EUR 3 million of venture capital financing. The money raised over the previous years enabled Icon Genetics to establish a strong research effort. "By raising venture capital under today’s less than favourable market conditions, Icon has demonstrated that we are", said Dr. Yuri Gleba, CEO.
 
In a another deal, Icon signed an exclusive license agreement with Xios Biomedicals, Inc., a New Jersey-based start-up, founded by Audax Ventures and Dr. N. Bascomb, former Icon’s shareholders, which is essentially a license-for-shares deal. As a result, Xios will receive an exclusive license to all Icon’s current technologies in the area of immune response protein production in plants.

Under a separate agreement, Xios also acquired former Icon’s research facilities in Monmouth Junction, New Jersey.

Dr. Newell Bascomb, formerly Icon’s President, left Icon and will be CEO and President of the new Company.
Prof. Dr. Yuri Gleba, CEO, will be the sole member of Icon’s Management Board.

The Supervisory Board of Icon Genetics AG will have a new member, Mr. Hendrik Liebers, Sachsen LB, Leipzig, who replaced Mr. John Maki (Audax Labs). Mr. Liebers will join the current members of the Supervisory board: Mr. Robert Erwin, Chairman, who is also CEO of Large Scale Biology Corp., Vacaville, CA, Prof. Dr. Hans-Ulrich Koop, co-founder of Icon Genetics (Vice Chairman), Dr. D. von der Osten, IBG, Magdeburg, Prof. U. Wobus, Institute of Plant Genetics and Crop Research, Gatersleben, and Prof. Dr. Meinhart Zenk, University of Halle-Wittenberg.